Loading…
Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study
Background : Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. Aim : To evaluate the effects of UDCA administration on acute viral hepatitis‐related cholestasis and the course of acute...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 1999-09, Vol.13 (9), p.1187-1193 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53 |
| container_end_page | 1193 |
| container_issue | 9 |
| container_start_page | 1187 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 13 |
| creator | Fabris Tositti Mazzella Zanetti Nicolin Pellizzer Benedetti De Lalla, F. |
| description | Background
: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases.
Aim
: To evaluate the effects of UDCA administration on acute viral hepatitis‐related cholestasis and the course of acute viral hepatitis.
Methods
: Seventy‐nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A‐E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals.
Results
: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed.
Conclusions
: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness. |
| doi_str_mv | 10.1046/j.1365-2036.1999.00592.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70001646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70001646</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53</originalsourceid><addsrcrecordid>eNqNkDtPwzAQgC0EoqXwF5AHxJZwThy3RiwV4iVVgqHMluPYqqs0LrZD239PQitgZLqT7rvXhxAmkBKg7GaZkpwVSQY5SwnnPAUoeJZuj9Dwp3CMhpAxnmQTkg_QWQhLAGBjyE7RoB8yGQMMkXowRquIncGtD67SbrtTC1dbhaWyFZbVyjY2RC-jdQ22DV53mW5iwBsbFx3URo0_rZc1Xui-Fm24xRKvbe0iDrGtdufoxMg66ItDHKH3x4f5_XMye316uZ_OEkVpniVszCvIS0lKWmkijS5UyQwtNPCCkEKXREFBOTGcTlhlxooZSTNaEs6AKFXkI3S9n7v27qPVIYqVDUrXtWy0a4PoHgbCKOvAyR5U3oXgtRFrb1fS7wQB0bsRS9F7FL1H0QsW34LFtmu9POxoy5Wu_jTujXbA1QGQQcnaeNkoG345TnkO_a13e2xja737934xfZt3Sf4FUPCXdg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70001646</pqid></control><display><type>article</type><title>Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Fabris ; Tositti ; Mazzella ; Zanetti ; Nicolin ; Pellizzer ; Benedetti ; De Lalla, F.</creator><creatorcontrib>Fabris ; Tositti ; Mazzella ; Zanetti ; Nicolin ; Pellizzer ; Benedetti ; De Lalla, F.</creatorcontrib><description>Background
: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases.
Aim
: To evaluate the effects of UDCA administration on acute viral hepatitis‐related cholestasis and the course of acute viral hepatitis.
Methods
: Seventy‐nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A‐E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals.
Results
: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed.
Conclusions
: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.1999.00592.x</identifier><identifier>PMID: 10468700</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>Acute Disease ; Adolescent ; Adult ; Aged ; Biological and medical sciences ; Chenodeoxycholic Acid - blood ; Cholagogues and Choleretics - blood ; Cholagogues and Choleretics - pharmacology ; Cholagogues and Choleretics - therapeutic use ; Cholestasis - drug therapy ; Cholestasis - etiology ; Cholic Acid - blood ; Digestive system ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Hepatitis Antibodies - blood ; Hepatitis Viruses - genetics ; Hepatitis Viruses - immunology ; Hepatitis, Viral, Human - complications ; Hepatitis, Viral, Human - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pilot Projects ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Viral - blood ; Treatment Outcome ; Ursodeoxycholic Acid - blood ; Ursodeoxycholic Acid - pharmacology ; Ursodeoxycholic Acid - therapeutic use</subject><ispartof>Alimentary pharmacology & therapeutics, 1999-09, Vol.13 (9), p.1187-1193</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53</citedby><cites>FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1949305$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10468700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabris</creatorcontrib><creatorcontrib>Tositti</creatorcontrib><creatorcontrib>Mazzella</creatorcontrib><creatorcontrib>Zanetti</creatorcontrib><creatorcontrib>Nicolin</creatorcontrib><creatorcontrib>Pellizzer</creatorcontrib><creatorcontrib>Benedetti</creatorcontrib><creatorcontrib>De Lalla, F.</creatorcontrib><title>Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background
: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases.
Aim
: To evaluate the effects of UDCA administration on acute viral hepatitis‐related cholestasis and the course of acute viral hepatitis.
Methods
: Seventy‐nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A‐E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals.
Results
: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed.
Conclusions
: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness.</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Chenodeoxycholic Acid - blood</subject><subject>Cholagogues and Choleretics - blood</subject><subject>Cholagogues and Choleretics - pharmacology</subject><subject>Cholagogues and Choleretics - therapeutic use</subject><subject>Cholestasis - drug therapy</subject><subject>Cholestasis - etiology</subject><subject>Cholic Acid - blood</subject><subject>Digestive system</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hepatitis Antibodies - blood</subject><subject>Hepatitis Viruses - genetics</subject><subject>Hepatitis Viruses - immunology</subject><subject>Hepatitis, Viral, Human - complications</subject><subject>Hepatitis, Viral, Human - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Viral - blood</subject><subject>Treatment Outcome</subject><subject>Ursodeoxycholic Acid - blood</subject><subject>Ursodeoxycholic Acid - pharmacology</subject><subject>Ursodeoxycholic Acid - therapeutic use</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqNkDtPwzAQgC0EoqXwF5AHxJZwThy3RiwV4iVVgqHMluPYqqs0LrZD239PQitgZLqT7rvXhxAmkBKg7GaZkpwVSQY5SwnnPAUoeJZuj9Dwp3CMhpAxnmQTkg_QWQhLAGBjyE7RoB8yGQMMkXowRquIncGtD67SbrtTC1dbhaWyFZbVyjY2RC-jdQ22DV53mW5iwBsbFx3URo0_rZc1Xui-Fm24xRKvbe0iDrGtdufoxMg66ItDHKH3x4f5_XMye316uZ_OEkVpniVszCvIS0lKWmkijS5UyQwtNPCCkEKXREFBOTGcTlhlxooZSTNaEs6AKFXkI3S9n7v27qPVIYqVDUrXtWy0a4PoHgbCKOvAyR5U3oXgtRFrb1fS7wQB0bsRS9F7FL1H0QsW34LFtmu9POxoy5Wu_jTujXbA1QGQQcnaeNkoG345TnkO_a13e2xja737934xfZt3Sf4FUPCXdg</recordid><startdate>199909</startdate><enddate>199909</enddate><creator>Fabris</creator><creator>Tositti</creator><creator>Mazzella</creator><creator>Zanetti</creator><creator>Nicolin</creator><creator>Pellizzer</creator><creator>Benedetti</creator><creator>De Lalla, F.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199909</creationdate><title>Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study</title><author>Fabris ; Tositti ; Mazzella ; Zanetti ; Nicolin ; Pellizzer ; Benedetti ; De Lalla, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Chenodeoxycholic Acid - blood</topic><topic>Cholagogues and Choleretics - blood</topic><topic>Cholagogues and Choleretics - pharmacology</topic><topic>Cholagogues and Choleretics - therapeutic use</topic><topic>Cholestasis - drug therapy</topic><topic>Cholestasis - etiology</topic><topic>Cholic Acid - blood</topic><topic>Digestive system</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hepatitis Antibodies - blood</topic><topic>Hepatitis Viruses - genetics</topic><topic>Hepatitis Viruses - immunology</topic><topic>Hepatitis, Viral, Human - complications</topic><topic>Hepatitis, Viral, Human - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Viral - blood</topic><topic>Treatment Outcome</topic><topic>Ursodeoxycholic Acid - blood</topic><topic>Ursodeoxycholic Acid - pharmacology</topic><topic>Ursodeoxycholic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabris</creatorcontrib><creatorcontrib>Tositti</creatorcontrib><creatorcontrib>Mazzella</creatorcontrib><creatorcontrib>Zanetti</creatorcontrib><creatorcontrib>Nicolin</creatorcontrib><creatorcontrib>Pellizzer</creatorcontrib><creatorcontrib>Benedetti</creatorcontrib><creatorcontrib>De Lalla, F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabris</au><au>Tositti</au><au>Mazzella</au><au>Zanetti</au><au>Nicolin</au><au>Pellizzer</au><au>Benedetti</au><au>De Lalla, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1999-09</date><risdate>1999</risdate><volume>13</volume><issue>9</issue><spage>1187</spage><epage>1193</epage><pages>1187-1193</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background
: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases.
Aim
: To evaluate the effects of UDCA administration on acute viral hepatitis‐related cholestasis and the course of acute viral hepatitis.
Methods
: Seventy‐nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A‐E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals.
Results
: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed.
Conclusions
: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>10468700</pmid><doi>10.1046/j.1365-2036.1999.00592.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 1999-09, Vol.13 (9), p.1187-1193 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70001646 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Acute Disease Adolescent Adult Aged Biological and medical sciences Chenodeoxycholic Acid - blood Cholagogues and Choleretics - blood Cholagogues and Choleretics - pharmacology Cholagogues and Choleretics - therapeutic use Cholestasis - drug therapy Cholestasis - etiology Cholic Acid - blood Digestive system Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Hepatitis Antibodies - blood Hepatitis Viruses - genetics Hepatitis Viruses - immunology Hepatitis, Viral, Human - complications Hepatitis, Viral, Human - drug therapy Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Pilot Projects Reverse Transcriptase Polymerase Chain Reaction RNA, Viral - blood Treatment Outcome Ursodeoxycholic Acid - blood Ursodeoxycholic Acid - pharmacology Ursodeoxycholic Acid - therapeutic use |
| title | Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20ursodeoxycholic%20acid%20administration%20in%20patients%20with%20acute%20viral%20hepatitis:%20a%20pilot%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Fabris&rft.date=1999-09&rft.volume=13&rft.issue=9&rft.spage=1187&rft.epage=1193&rft.pages=1187-1193&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.1999.00592.x&rft_dat=%3Cproquest_cross%3E70001646%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4432-679d03ba1b4de1afe5cb6f45e095115eb1c05491f9486df7c6fa424b19601cc53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70001646&rft_id=info:pmid/10468700&rfr_iscdi=true |